tyrosine has been researched along with defactinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonifaci, N; Cabiscol, E; Castellà, G; Coll, L; Fajas, L; Gari, E; Gatius, S; Llobet-Navàs, D; Lopez-Mejia, IC; Matias-Guiu, X; Navaridas, R; Panosa, A; Peña, LP; Pijuan, J; Pinyol, M; Santacana, M; Velasco, A; Vidal, A; Villanueva, A; Yeramian, A | 1 |
1 other study(ies) available for tyrosine and defactinib
| Article | Year |
|---|---|
Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness.
Topics: Animals; Antioxidants; Cell Line, Tumor; Cell Movement; Cystadenocarcinoma, Serous; Focal Adhesion Kinase 1; Humans; Oxidative Stress; Phosphorylation; Reactive Oxygen Species; Tyrosine | 2023 |